Red flags like promoter reducing stake + MD resigning are there.
Still tracking because, it is trying to move up the value chain and offering customised services, pivot from a generic testing company. (Like a CRAMS player expanding/specialising their portfolio, spending more on R&D)
Will look for margin expansion to happen.
If any other views pls share.
Subscribe To Our Free Newsletter |